Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas A Lanz

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Plos One|June 5, 2020
GluN2D-mediated excitatory drive onto medial prefrontal cortical PV+ fast-spiking inhibitory interneuronsJonathan Garst-Orozco, Ruchi Malik, Thomas A Lanz, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|October 13, 2020
An in vitro alveolar epithelial cell model recapitulates LRRK2 inhibitor-induced increases in lamellar body size observed in preclinical modelsJulie Harney, Piyush Bajaj, James E Finley, et al.
Toxicology and Applied Pharmacology|January 14, 2025
In vitro NIH3T3 mouse embryonic fibroblast cell model does not predict AAV2 or AAVdj-mediated cell transformationLuping Qiu, Steven W Kumpf, Elias M Oziolor, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 7, 2010
Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's diseaseRobin J Kleiman, Lida H Kimmel, Susan E Bove, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|June 8, 2012
Robust changes in expression of brain-derived neurotrophic factor (BDNF) mRNA and protein across the brain do not translate to detectable changes in BDNF levels in CSF or plasmaThomas A Lanz, Susan E Bove, Catherine D Pilsmaker, et al.
Scientific Data|May 30, 2026
Quantitative transcriptome and proteome maps of classical nonclinical speciesElias Oziolor, Liang Xue, Dennis Pelletier, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 9, 2012
MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain functionBrooke H Miller, Zane Zeier, Li Xi, et al.
Cancer Immunology, Immunotherapy : CII|May 3, 2025
Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injuryChanghua Ji, Steven Kumpf, Jessie Qian, et al.
Journal of Parkinson'S Disease|February 3, 2020
An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 CohortsShalini Padmanabhan, Thomas A Lanz, Donal Gorman, et al.
Molecular Therapy. Methods & Clinical Development|November 11, 2024
Single cell and TCR analysis of immune cells from AAV gene therapy-dosed Duchenne muscular dystrophy patientsMichael R Emami, Mark A Brimble, Alejandro Espinoza, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Plos One|June 5, 2020
GluN2D-mediated excitatory drive onto medial prefrontal cortical PV+ fast-spiking inhibitory interneuronsJonathan Garst-Orozco, Ruchi Malik, Thomas A Lanz, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|October 13, 2020
An in vitro alveolar epithelial cell model recapitulates LRRK2 inhibitor-induced increases in lamellar body size observed in preclinical modelsJulie Harney, Piyush Bajaj, James E Finley, et al.
Toxicology and Applied Pharmacology|January 14, 2025
In vitro NIH3T3 mouse embryonic fibroblast cell model does not predict AAV2 or AAVdj-mediated cell transformationLuping Qiu, Steven W Kumpf, Elias M Oziolor, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 7, 2010
Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's diseaseRobin J Kleiman, Lida H Kimmel, Susan E Bove, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|June 8, 2012
Robust changes in expression of brain-derived neurotrophic factor (BDNF) mRNA and protein across the brain do not translate to detectable changes in BDNF levels in CSF or plasmaThomas A Lanz, Susan E Bove, Catherine D Pilsmaker, et al.
Scientific Data|May 30, 2026
Quantitative transcriptome and proteome maps of classical nonclinical speciesElias Oziolor, Liang Xue, Dennis Pelletier, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 9, 2012
MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain functionBrooke H Miller, Zane Zeier, Li Xi, et al.
Cancer Immunology, Immunotherapy : CII|May 3, 2025
Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injuryChanghua Ji, Steven Kumpf, Jessie Qian, et al.
Journal of Parkinson'S Disease|February 3, 2020
An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 CohortsShalini Padmanabhan, Thomas A Lanz, Donal Gorman, et al.
Molecular Therapy. Methods & Clinical Development|November 11, 2024
Single cell and TCR analysis of immune cells from AAV gene therapy-dosed Duchenne muscular dystrophy patientsMichael R Emami, Mark A Brimble, Alejandro Espinoza, et al.
Pageof 5